AAO 2020 Virtual

    In this interview from AAO 2020 Virtual, Dr. Jeffrey Heier discusses post-marketing reports of intraocular inflammation after brolucizumab treatment. During his Retina Subspeciality Day talk, he shared work done by a coalition of Novartis team members and outside global experts on patient characteristics and risk factors for treatment-related inflammation the HAWK and HARRIER trials. The most important finding, he explained, was that antidrug antibodies were either boosted or emergent in these patients, and appear to have a relationship with occlusive disease or vasculitis. He hopes these findings will be further validated in ongoing Novartis studies. 

    To learn more, watch Dr. Heier’s talk, “Assessing Characteristics of Patients With or Without Intraocular Inflammation (IOI) In the Brolucizumab Treatment Arms From the HAWK and HARRIER, Phase 3 Studies” during the “Late Breaking Developments, Part 1” session (RET10V).

    Relevant Financial Disclosures: Dr. Heier is a consultant and receives grant support from Novartis.